N4 Pharma (LON:N4P) Shares Up 10.4% – Should You Buy?

Shares of N4 Pharma Plc (LON:N4P) were up 10.4% during mid-day trading on Friday . The company traded as high as GBX 0.70 ($0.01) and last traded at GBX 0.69 ($0.01). Approximately 4,099,860 shares changed hands during trading, an increase of 63% from the average daily volume of 2,521,318 shares. The stock had previously closed at GBX 0.63 ($0.01).

N4 Pharma Stock Up 10.4%

The stock’s fifty day moving average price is GBX 0.50 and its 200-day moving average price is GBX 0.46. The company has a market capitalization of £5.74 million, a price-to-earnings ratio of -222.58 and a beta of -0.37.

N4 Pharma (LON:N4P) last issued its quarterly earnings results on Thursday, September 25th. The company reported GBX (0.09) earnings per share (EPS) for the quarter. N4 Pharma had a negative return on equity of 90.68% and a negative net margin of 18,399.86%.

N4 Pharma Company Profile

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.